Georgina V Long

发表

Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis.

Jason Li, Antoni Ribas, Rodney J Hicks, 2014, Cancer discovery.

Tumor-associated B-cells induce tumor heterogeneity and therapy resistance

Johannes Griss, Zhi Wei, Jie Zhang, 2017, Nature Communications.

Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma

Lauren E Haydu, Richard A Scolyer, R. Scolyer, 2012, Clinical Cancer Research.

Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis.

Matthew Wongchenko, Jeffrey E Gershenwald, Lauren E Haydu, 2018, The Lancet. Oncology.

Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial.

Ying Zhang, Jean-Jacques Grob, Keith T Flaherty, 2017, The Lancet. Oncology.

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

Dirk Schadendorf, Reinhard Dummer, Paolo A Ascierto, 2015, The New England journal of medicine.

Reply to M. Perier-Muzet et al.

Lauren E Haydu, Dirk Schadendorf, Richard A Scolyer, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Inhibition of mTORC1/2 overcomes resistance to MAPK pathway inhibitors mediated by PGC1α and oxidative phosphorylation in melanoma.

Kakajan Komurov, Gordon B Mills, Prahlad T. Ram, 2014, Cancer research.

Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual

Jeffrey E Gershenwald, Lauren E Haydu, Merrick I Ross, 2017, CA: a cancer journal for clinicians.

Systemic therapy in advanced melanoma: integrating targeted therapy and immunotherapy into clinical practice

G. Long, Georgina V Long, Inês P Silva, 2017, Current opinion in oncology.

Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy.

Antoni Ribas, Hubing Shi, Mark C Kelley, 2014, Cancer discovery.

Dabrafenib and its potential for the treatment of metastatic melanoma

G. Long, A. Menzies, R. Murali, 2012, Drug design, development and therapy.

A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition.

Antoni Ribas, Hubing Shi, Richard A Scolyer, 2014, Cancer discovery.

Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib.

Jeffrey Weber, Keith T Flaherty, Zeynep Eroglu, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Computer-assisted diagnosis for skin cancer: have we been outsmarted?

Richard A Scolyer, R. Scolyer, G. Long, 2017, The Lancet.

Comparison of whole-exome sequencing of matched fresh and formalin fixed paraffin embedded melanoma tumours: implications for clinical decision making.

Marcel E Dinger, Graham J Mann, Richard A Scolyer, 2016, Pathology.